Ruxolitinib Best for Glucocorticoid - Refractory, - Dependent GVHD

Overall response, failure - free survival, symptom response significantly greater with ruxolitinib versus control therapy
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Journal, Source Type: news